

LeRoy A. Jones, Jr. M.D.
Urology San Antonio

EDUCATION:

1978-1980	Potsdam College Potsdam, New York No degree earned.
1980-1983	University of Colorado Boulder, Colorado Bachelor of Arts in Chemistry
1984-1988	Washington University School of Medicine St. Louis, Missouri Doctorate of Medicine
1988-1990	John Hopkins Hospital Dept. of Surgery Baltimore, Maryland Internship, Assistant Resident
1990-1994	Baylor College of Medicine Scott Dept. of Urology Houston, Texas Residency

WORK EXPERIENCE:

2004-Present	Urology San Antonio Research, PA San Antonio, Texas Investigator
2004-Present	Urology San Antonio, PA 7909 Fredericksburg Rd. Suite 120 San Antonio, Texas 78229 Group Practice-Urologist
2000-2004	University of Texas Health Science Center San Antonio, Texas Urologist
1999-2000	Kelsey-Seybold Clinic Houston, Texas

CREDENTIALS:

1996	Diplomate American Board of Urology
2004	Re-Certified

ACADEMIC APPOINTMENTS:

1994-1998	University of New Mexico Health Science Center Division of Urology
-----------	-----------------------------------------------------------------------

Albuquerque, New Mexico
Assistant Professor of Surgery

1998-1999 Baylor College of Medicine
Scott Department of Urology
Houston, Texas
Assistant Professor of Urology

1999-2000 Baylor College of Medicine
Scott Department of Urology
Houston, Texas
Clinical Assistant Professor of Urology

2000-Present University of Texas Health Science Center San Antonio
Head, Section of Sexual Medicine
San Antonio, Texas
Assistant Professor of Urology

HOSPITAL AFFILIATIONS:

2000-Present Baptist Health Systems
San Antonio, Texas
Medical Staff Member

2000-Present Christus Santa Rosa Healthcare Systems
San Antonio, Texas
Medical Staff Member

2000-Present Methodist Healthcare Systems
San Antonio, Texas
Medical Staff Member

2000-Present Attending Urologist
University Hospital System
San Antonio, Texas 78229

PROFESSIONAL AFFILIATIONS:

American Urological Society
Baltimore, Maryland
Active Member

South Central Section of AUA
Baltimore, Maryland
Active Member

Sexual Medicine Society – North America
Schaumburg, Illinois
Active Member

International Society for the Study of Women’s Sexual Health
Schaumburg, Illinois
Active Member

APPOINTMENTS:

1994-1998 The Western Journal of Medicine
San Francisco, California
Advisory Board, Clinical Investigation

2001-Present Cancer
Houston, Texas
Reviewer

INSTRUCTOR POST GRADUATE COURSE:

Transurethral Urological Techniques With Nd: YAG
Lasers and Electrovaporization
1995

Surgical Techniques of Inflatable Penile Prosthesis
Santa Rosa Hospital, San Antonio, Texas
1/28/2002

Surgical Techniques of Inflatable Penile Prosthesis
Santa Rosa Hospital , San Antonio Texas
2/9/2004

VIDEO PRODUCTION:

Transcrotal Placement of the Artificial Urinary Sphincter
Presented International Continence Society Annual Meeting
Florence, Italy 2003

Prostate Cancer Education for Primary Care Providers, 2003

PRESENTATIONS:

1. Hyperprolactinemia – It’s Role in Male Fertility
Le Roy A. Jones and Larry Lipshultz
1992 AUA-Washington, DC
2. Modification of the Glans Approximation Procedure
Le Roy A. Jones and David Roth
1993 South Central Section of the AUA- Acapulco, Mexico
3. Retrograde Percutaneous Nephrostomy Tube Placement
1996 New Mexico Urologic Society- Albuquerque, New Mexico
4. Varicocelectomy-Indications in 1997
1997 New Mexico Urologic Society- Albuquerque, New Mexico
5. Evaluation and Management of the Spinal Cord Injured Patient
1997 Health South Rehabilitation Conference- Albuquerque, New Mexico

6. Update of Interstitial Cystitis
1997 Fifth Innovations In Urology Conference- Santa Fe, New Mexico
7. Surgery for Stress Incontinence- How are we doing?
1997 Fifth Innovations In Urology Conference- Santa Fe, New Mexico
8. Interstitial Cystitis in 1998
New Mexico Urologic Society-Albuquerque, New Mexico
9. Voiding Dysfunction with Common Peripheral Neuropathies
1998 Sixth Innovations in Urology-Santa Fe, New Mexico
10. Sexual Dysfunction in the Aging
2001 Exploring Clinical Advances in Geriatric Care-San Antonio,Texas
11. Male and Female Sexual Medicine
2001 Society of Urologic Nurses and Associates-San Antonio, Texas
12. Female Sexual Dysfunction
2001 Multiple Sclerosis Society-Austin, Texas
13. Female Sexual Medicine
Howard Radwin Annual Urologic Review
2001 Division of Urology, San Antonio, Texas
14. Prostate Cancer Screening for Primary Care Providers
26th Annual Family Practice Review Course
2002 UTHSCSA, San Antonio, Texas
15. Prostate Cancer Screening for Primary Care Providers
American Geriatrics Society
2002 Washington, DC
16. Sexual Medicine in 2002, Update on Oral Therapy
Austin Urological Society
2002 Austin, Texas
17. Sexual Medicine in the Geriatric Patient
UTHSCSA Annual Geriatric Review Conference
2002 San Antonio, Texas
18. Prostate Cancer Screening
National Medical Association
2002 Maui, Hawaii
19. Sexual Dysfunction and Prostate Cancer
23rd Annual Conference on Aging
2002 San Antonio, Texas
20. Ethnic Considerations in the Treatment of Sexual Dysfunction
Texas Academy of Family Physicians
2002 Houston, Texas
21. Sexual Health in the Diabetic Patient
South Chapter, Texas Academy of Family Physicians

- 2002 Corpus Christi, Texas
22. Erectile Dysfunction
27th Annual Family Practice Review Course
2003 UTHSCSA, San Antonio, Texas
 23. Male Sexual Dysfunction
Bexar County Physician Assistant Society
2003 Alamo CME Conference & Expo
San Antonio, Texas
 24. Sexual Dysfunction, The Couple's Disease
34th Annual Conference 2003
Society of Urologic Nurses and Associates
San Antonio, Texas
 25. Male Sexual Health Symposium CME
UMDNJ
Houston, Texas 2003
 26. Sexual Health Symposium CME
Boston University
San Antonio, Texas 2003
 27. Male Sexual Health
Austin Urologic Society
Austin, Texas 2004
 28. Family Practice Urology Update CME
University of British Columbia
Vancouver, BC 2004
 29. Sexual Medicine Society, North America
Winter Research Meeting
"Corporal Fibrosis and the Difficult Penile Implant"
New Orleans, Louisiana 2005

PUBLICATIONS:

1. Hyperprolactinemia, its role in male infertility. Jones LA and Lipshultz L, J Urol, AUA Abstract Edition 1992
2. The use of validated questionnaires to assess female sexual dysfunction
Jones, LA. World Journal Urology. (2002) 20:89-92
3. The Retained Reservoir in Penile prosthesis explantation, Jones LA, Ryan R, Wilson SK, J Urol, AUA Abstract Edition 2002
4. Female Sexual Dysfunction in Interstitial Cystitis
Teichman J, French D, Jones L, J Urol 2003 (Submitted)
5. Septicemia Following Intracavernosal Injection Therapy for Erectile Dysfunction in a Diabetic Male
Nalesnik J, Jones L, Kraus S, J Urol 2003 (accepted)

6. Minimally Invasive Placement of the Artificial Urinary Sphincter
Leslie J, Jones L. World Journal Urology 2004 (submitted)
7. Cost and Time Benefits of Dual Implantation of Inflatable Penile Prosthesis and Artificial Urinary Sphincter Prosthetics by Single Incision
Sellers C, Morey A, Jones L, Urology 65: 852-854, 2005

INVITED PUBLICATIONS:

1. The Next Generation of Phosphodiesterase Type 5 Inhibitors
AUA Times
November 2003
2. Preservation of Erectile Function after Radical Prostatectomy
French D, Jones L
Cancer (submitted for 2005 edition)
3. Prostate Disorders in Minority Populations
French D, Jones L
Medical Clinics of North America 89 (2005) 805-816

VISITING PROFESSORSHIPS:

- | | |
|-----------------|---------------------------------------------------------------------------|
| 2/14/02-2/15/02 | University of New Mexico Health Science Center
Albuquerque, New Mexico |
| 4/7/03-4/10/03 | University of British Columbia
Vancouver, Canada |
| 4/2004 | Texas A&M University
Scott and White Clinic
Temple, Texas |

CLINICAL RESEARCH EXPERIENCE:

1. "Nerve Regeneration for Erectile Function following Radical Retropubic Prostatectomy"
2. "Efficacy of Tadalafil (subpopulation studies)"
3. "Prevalence of Erectile Dysfunction in Hispanic Diabetic Males"
4. "Diagnosis of Female Sexual Dysfunction in patients with Interstitial Cystitis"
5. "CDC: Professional Education on Prostate Cancer for Primary Health Care Providers"
6. "SWOG JPR.3 Intergroup Phase III Randomized Trial Comparing Total Androgen Blockage versus Total Androgen Blockade plus Pelvic Irradiation in Clinical Stage T3-4, N0, M0 Adenocarcinoma of the Prostate"
7. "SWOG 9450 Prostate Cancer Intervention versus Observation Trial (PIVOT)"

8. "SWOG 0000 SELECT: Selenium and Vitamin E Cancer Prevention Trial"
9. "San Antonio Prostate Cancer Study of Biomarkers of Health (SABOR
10. "A randomized, double-blind, placebo-controlled, multicenter efficacy and safety study for the prevention of Prostate Cancer in men with High Grade Prostatic Intraepithelial Neoplasia (PIN)."
11. "Diagnostic Molecular Marker for Prostate Cancer Screening."
12. "Psychometric Validation of the OAB family Impact Measure."
13. "A Randomized, Double-Blind, placebo-controlled, parallel arm, multi center trial Assessing the effect of daily treatment of XXXX 20 mg or XXXX 100 mg compared To placebo on spermatogenesis, mean sperm concentration, sperm count, morphology, and motility reproductive hormones in healthy males or males with mild erectile Dysfunction."
14. "A phase 2, 8-week, multicenter, randomized double-blind, placebo controlled, parallel group study evaluating the efficacy, tolerability and safety of [X,X] XXXXX (XXXXX) for stress urinary incontinence in women."
15. "An open-label, multicentre, randomized parallel group comparison of efficacy and safety of XXXXthree-month depot in three different dosing regimens of 240 mg (40mg/ml) and 240 (60mg/ml) in patients with Prostate Cancer requiring Androgen Ablation Therapy"
16. "Multicenter Randomized Double-Blind, Placebo-Controlled Switch Study Of Men With Mild ED To Evaluate The Efficacy Of XXXX 8 Hours Post-Dose."
17. "A Phase 2 Multi-Center, Open Label, Long-term Extension Trail to Assess The Safety and Sustained Efficacy of Oral XXXX Administered As Required in Adult Men with Premature Ejaculation."
18. "A Placebo-Controlled, Double-Blind, Randomized, Parallel Study of the Withdraw Effects of Chronic Daily and As Needed Dosing With XXXX in the Treatment of Premature Ejaculation."
19. "A multicenter, Parallel-Arm, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of XXXX Administered Once Daily to Men with Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia."
20. "A multicenter, double-blind, randomized study to compare the efficacy and safety of XXXX 750 MG once daily for five days versus XXXXX twice daily for ten days in the treatment of complicated urinary tract infection or acute Pyelonephritis."
21. "A Randomized, Double-Blind, Triple-Dummy, Parallel-Group Study to Investigate the Effects of a Single Oral Dose of XXXX on Urodynamic Parameters in Patients with Overactive Bladder."
22. "A Placebo-Controlled, Randomized, Double-Blind, Fixed-Dose, At-Home Study to Evaluate the Efficacy and Safety of Intranasally Administered XXXX in Subjects with Erectile Dysfunction."
23. "A Placebo-Controlled, Randomized, Double-Blind, Fixed-Dose, At-Home Study to Evaluate the Efficacy and Safety of Intranasally Administered XXXX in Subjects with Erectile Dysfunction and Diabetes Mellitus."
24. "A Phase II Randomized, Sham-Controlled, Double-Blind, Dose-Finding Study to Assess the Efficacy and Safety of Transurethral Photodynamic Therapy with XXXX in Subjects with Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia."

25. "A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Evaluation of the Efficacy and Safety of XXXX in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia."
26. "A Randomized, Double-Blind, Placebo-Controlled, Dose Comparison Study of the Efficacy and Safety of XXXX for the Treatment of Symptomatic Benign Prostatic Hyperplasia."
27. "Phase II Study of XXXX XXXX in Patients with Bladder Cancer."
28. "A Multi-Center Open-Label Evaluation of the Safety of XXXX in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia."
29. "A Phase II, Randomized, Multi-Center, Placebo-Controlled, Double-Blind, Dose-Ranging Clinical Trial to Study the Efficacy and Safety of XXXX XXXX for the Treatment of Hot Flashes Following Surgical or Medical Castration of Prostate Cancer Patients."
30. "Developing Psychometrically Validated Scales to Measure Sexual Functioning in Relationship to Peyronie's Disease."
31. "An Open-Label, Multi-Center, Randomized, Parallel-Group Study, Investigating the Efficacy and Safety of XXXX One Month Dosing Regimens; XXXX and XXXX, in Comparison to XXXX in Patients with Prostate Cancer Requiring Androgen Ablation Therapy."
32. "A Multi-Center, Randomized Clinical Investigation of XXXX Versus Continued Therapy in Patients Receiving XXXX or XXXX for Advanced Prostate Cancer."
33. "A Forty-Eight Week, Randomized Discontinuation Trial of XXXX in Women with Hypoactive Sexual Desire Disorder Containing an Open-Label, Flexible Dose Period Followed by a Double-Blind, Randomized, Placebo-Controlled Period."
34. "A Randomized, Placebo-Controlled, Double-Blind, Parallel Design Trial of the Efficacy and Safety of XXXX in Women with Mixed Desire/Interest/Arousal/Orgasm Disorders."
35. "A Multi-Center, Double-Blind, Randomized, Placebo and Active-Controlled, Parallel-Group, Dose-Ranging Study of XXXX in Patients with Overactive Bladder."
36. "An Open-Label, Multi-Center, Extension Study, evaluating the Long-Term Safety and Tolerability of Different Three-Month XXXX Dosing Regimens, XXXX, XXXX, in Patients with Prostate Cancer."
37. "A Feasibility Evaluation of the XXXX XXXX in Facilitating the Vesico-urethral Anastomosis Following a Radical Prostatectomy."
38. "A Pre-Market Study of the XXXX for the Treatment of Male Stress Urinary Incontinence."
39. "A Phase III Multi-Center, Open-Label, Randomized Evaluation in Hypogonadal Male Subjects of the Pharmacokinetics and Safety of a Dose Regimen of XXXX, a Novel Testosterone Transmucosal Film Formulation, and Striant (Testosterone Buccal System) Mucoadhesive."
40. "A Phase III, open-label, multi-center study of the efficacy and safety of XXXX in the treatment of Patients with non-muscle invasive (superficial) bladder cancer at high risk of progression and who are refractory to BCG."
41. "A Phase III, open-label, multi-center study of the efficacy and safety of XXXXX in the treatment of patients with non-muscle invasive (superficial) bladder cancer at high risk of progression and who are refractory to BCG."

42. "A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Repeat Treatment with Two Dose Levels of XXXXX (XXXXX) XXXXX Followed by a Treatment with XXXXX in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity."
43. "A Twenty Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of XXXXX 50 milligrams Daily and, with Uptitration, 100 Milligrams Daily in Premenopausal Women with Hypoactive Sexual Desire Disorder."
44. "A Phase III Radomized, Open-Label Study of XXXXX and XXXXX Versus Docetaxel and Prednisone in Patients with Metastatic Hormone-Refractory Prostate cancer who are Chemotherapy-Naïve."
45. "Post-Marketing Study Using XXXXX for the Treatment of Benign Prostatic Hyperplasia (BPH)."
46. "A Multi-Center Clinical Study of the XXXXX for the Treatment of Localized (T1cT2a) Prostate Cancer with HIFU."
47. "A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of XXXXX in Extending the Time to Progression of Low-Risk Localized Prostate Cancer in Men who are Candidates for or Undergoing Expectant Management."
48. "A Two-Arm, Open-Label, Randomized, Multi-Center Pharmacokinetic and Long-term Safety Study of XXXXX Testosterone Undecanoate in Hypogonadal Men."
49. "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, 5-Group, Multinational Study to Evaluate the Efficacy, Dose Response, and Safety of XXXXX Once-a-Day Dosing for 12 Weeks in Men with Signs and Symptoms of Benign Prostatic Hyperplasia."
50. "XXXXX 5 mg Once a Day Compared to Placebo in Improving Erectile Dysfunction and Sexual Quality of Life."
51. "A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group, Dose-Ranging Study of XXXXX in Patients with Overactive Bladder."
52. "A Phase II Randomised, Two-way Crossover Study to Compare the Steady State Pharmacokinetics of Testosterone following application of different XXXXX doses in hypogonadal male subjects."
53. "A Phase III, Randomized, Double-Blind, Placebo-Controlled, and Open-Label Active-Controlled Study to Evaluate the Safety and Efficacy of XXXXX Treatment in Men with Secondary Hypogonadism."
54. "A Phase 1 Trial of XXXXX Therapy for locally Recurrent Prostate Cancer without Metastases after Primary Radiation Therapy."
55. "A Multicentre, Placebo Controlled, Randomised, Double-Blind, Dose Ranging Study of XXXXX and Placebo Daily Doses for 4 Weeks in Patients Suffering From Overactive Bladder Syndrome."
56. "A Multicenter, Open-Label, Randomized, Phase III Trial Comparing Immediate Adjuvant Hormonal Therapy (XXXXX) in combination with XXXXX Administred Every Three Weeks Versus Hormonal Therapy Alone Versus Deferred Therapy Followed by the Same Therapeutic Options in Patients with Prostate Cancer at High Risk After Radical Prostatectomy."

57. "Pilot Study of the Intervesimal Administration of XXXXX Immediately Following Transurethral Resection in Patients with Superficial Bladder Cancer."
58. "Phase Ib placebo-controlled trial of XXXXX in the study of modulation of intermediate endpoint markers in patients with prostate cancer who are undergoing prostatectomy."
59. "A Multi-Center, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Dosing with XXXXX to Treat the Symptoms of Overactive Bladder with a 14-Week Open-Label Safety Extension."
60. "A randomized double blind phase III study to evaluate adjuvant XXXXX treatment versus placebo in patients with clear cell XXXXX and high risk of recurrence."
61. "XXXXX IM dosage regimens in patients with symptomatic BPH, a 1 year placebo-controlled efficacy study and long-term safety assessment."
62. "XXXXX IM dosage regimens in patients with symptomatic BPH, a 1 year placebo-controlled efficacy study and long-term safety assessment."
63. "A Randomized, Double-Blind, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of XXXXX in Men with Prostate Cancer Receiving Androgen Deprivation Therapy."
64. "A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of XXXXX for the Treatment of Hypogonadal Men."
65. "Prospective Multi-Center Study to Evaluate the Diagnostic Performance of the XXXXX for Prostate Cancer Screening."
66. "An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of XXXXX One-Month Dosing Regimen in Patients with Prostate Cancer Requiring XXXXX."
67. "Long Term Effectiveness Trial for AMS Sling Systems MiniArc"
68. "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XXXXX Vs. XXXXX in Combination XXXXX in Patients with Metastatic Hormone-Resistant Prostate Cancer and Bone Metastasis who are Pain-Free or Mildly Symptomatic"
69. "A Phase 3, Randomized, Open-Label Study of XXXXX in Combination with XXXXX and XXXXX Versus XXXXX and XXXXX in Taxane-Naïve Patients with Metastatic Hormone-Refractory Prostate Cancer with Pain"
70. "TITAN OTR Clinical Trial"
71. "Evaluation of the PCA3 Assay and Algorithms Combining PCA3 Score with other Factors for the Prediction of Biopsy Outcome and Pathological Stage"
72. "A Phase I, Randomized, Double Blind, Placebo-Controlled Assessment of the Safety, Tolerability and Activity of XXXXX Ointment for the Treatment of External Genital and Perianal Warts Caused by Human Papilloma Virus Infection"
73. "A Randomized, Double-Blind, Placebo Controlled, Parallel-Design, Multicenter study to Evaluate the Urodynamic Effects of XXXXX Once-A-Day for 12 Weeks in Men with Signs and Symptoms of Benign Prostatic Hyperplasia"

74. "An Open-Label Phase 3 Study of XXXXX Testosterone Gel 2% in Hypogonadal Males"
75. "A 12 Week, Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel-Group, Multi-Center Trial to Evaluate the Efficacy and Safety of a XXXXX in Comparison with XXXXX in Patients with Overactive Bladder"
76. "Prospective Randomized Double-Blind Study of Sperm Production in Healthy Volunteers Receiving XXXXX or Placebo"
77. "An Open-Label, Multi-Center, Phase Iia Trial of PRX302 Treatment of Patients with Locally Recurrent Prostate Cancer After Primary Radiation Therapy"
78. "A Multi-Center, Open-Label, Randomized, Phase III Trial Comparing Immediate Adjuvant Hormonal Therapy in Combination with XXXXX Administered every 3 Weeks Versus Hormonal Therapy Alone Versus Deferred Therapy Followed by the Same Therapeutic Options in Patients with Prostate Cancer at High Risk of Relapse After Radical Prostatectomy"
79. "A Phase 3, Multi-Center, Open-Label Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Two 6-Month XXXXX formulations, in Subjects with Prostatic Adenocarcinoma"
80. "Performance Evaluation of Optimized Kit Components and Process"
81. "GeneSearch Prostate Methylation Urine (Pro Mu) Assay"
82. "A Randomized, Double-Blind, Placebo-Controlled, Multicenter Cross-Over Study to Investigate the Pharmacodynamic Profile of XXXXX in Subjects with Pelvic Pain of Bladder Origin"
83. A Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of a Novel Nutritional Supplement on PSA Kinetics in Men with Biochemical Recurrence after Definitive Therapy for Prostate Cancer
84. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of XXXXX in the Treatment of External Genital Warts
85. A Phase II/III Controlled Study to Evaluate the Effectiveness of the Induced Reflex Cough Test Plus Urodynamics to Identify Stress Urinary Incontinence in Female Subjects with a History of Stress Urinary Incontinence
86. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Long-Term Safety and Efficacy of XXXXX for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women
87. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of XXXXX for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
88. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety and Efficacy of Daily Tadalafil for Twelve Weeks in Men with Signs and Symptoms of Benign Prostatic Hyperplasia on Concomitant Alpha1 Adrenergic Blocker Therapy
89. A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multinational Study to Evaluate the Efficacy and Safety of Tadalafil 2.5 and 5 mg Once Daily Dosing for 12 Weeks for the Treatment of Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia in Men with Both Erectile Dysfunction and Benign Prostatic Hyperplasia

90. XXXXX 2.5 mg and 5 mg once a Day Compared to Placebo in Day of Onset of Efficacy
91. Phase 3 Multicenter, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Clinical Evaluation of XXXXX for the Treatment of BPH
92. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of XXXXX, in Patients with Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hypertrophy (BPH)
93. Study of Urgent PC vs. Sham Effectiveness in Treatment of Overactive Bladder Symptoms
94. Efficacy and Safety of a New XXXXX 11.25mg Depot Formulation, XXXXX, When Given as Palliative Treatment to Prostate Cancer Patients
95. Hypoactive Sexual Desire Disorder in Women Registry
96. Validation of the AutoFISH XXXXX Bladder Cancer Kit on the XXXXX Automated Slide Staining System Specimen Collection and Specimen Testing Protocol
97. A Phase III, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Once-Daily Orally Administered XXXXX in 10mg in Non-Metastatic Hormone-Resistant Prostate Cancer Patients
98. Study of the Effects of XXXXX on Cardiac Repolarization in Subjects at Risk of Severe Thrombocytopenia after Myelosuppressive Chemotherapy
99. Prostatic Free Zinc for Prostate Cancer Diagnosis
100. Development Clinical Sample Collection Protocol
101. Clinical Evaluation of the XXXXX Assay in Men with a Previous Negative Biopsy Result
102. Bladder Cancer Recurrence Surveillance Trial
103. Hematuria Evaluation Trial
104. Double-Blind, Placebo-Controlled, Concentration-Escalating, Pharmacokinetic Study Evaluation the Systemic Absorption, Safety and Efficacy of XXXXX in Subjects Undergoing Ureteroscopic Treatment of Ureteral-or Renal Collecting System-Located Stones
105. A Phase II Randomized, Placebo-Controlled Trial of XXXXX to Evaluate Bladder Tissue Levels of EGCG
106. A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of XXXXX (XXXXX) in the Treatment of Erectile Dysfunction in Diabetic Men
107. A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of the Safety and Efficacy of XXXXX in the Treatment of Erectile Dysfunction Following Bilateral Nerve-Sparing Radical Prostatectomy
108. A Multi-center, Long-term follow up study of the safety and efficacy of two doses of XXXXX (XXXXX) purified neurotoxin complex in patients with urinary incontinence due to neurogenic detrusor overactivity
109. A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of a Single Treatment of XXXXX (XXXXX) Purified Neurotoxin Complex

- Followed by a Treatment with XXXXX as Applicable in Patients with Idiopathic Overactive Bladder with Urinary Incontinence
110. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of XXXXX (XXXXX) Plus XXXXX in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer
 111. A Randomized, Placebo-controlled, Double-Blind, Parallel Design, Phase 3 Study to Assess the Safety and Efficacy of XXXXX Tablets in Male Subjects with Erectile Dysfunction
 112. A Randomized, Placebo-controlled, Double-Blind, Parallel Design Phase 3, 12-Week Study to Assess the Safety and Efficacy of XXXXX Tablets in Male Subjects with Erectile Dysfunction
 113. An Open-Label, Multi-Centre, Randomised, Parallel-Arm One-Year Trial, Comparing the Efficacy and Safety of XXXXX Three-Month Dosing Regimen with XXXXX in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy
 114. A Double-Blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects with Non-metastatic Prostate Cancer Receiving XXXXX for Bone Loss due to Androgen-Deprivation Therapy
 115. Qualitative interview study to categorize men with low sexual desire and related stress
 116. A Phase I Study to Evaluate the Safety and Effectiveness of Using the XXXXX BPH System in Patients with Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH) who are Candidates for Interventional Therapy
 117. A Multi-Center, Double-Blind, Placebo-Controlled Investigation of XXXXX in the Treatment of Subjects with Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome
 118. A Phase 2 Clinical Study to Evaluate Daily Oral Doses of XXXXX for 24 Weeks in Men with Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia
 119. A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effectiveness of XXXXX Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2x4) in Men with Peyronie's Disease
 120. Effect of XXXXX on Spermatogenesis: A Double-Blind, Randomized, Placebo-controlled, Parallel-group Study
 121. A Double-Blind, Placebo-Controlled Study of XXXXX to Facilitate Urinary Stone Passage
 122. Vitros tPSA and Vitros fPSA Sample Collection Protocol
 123. An Open-Label, Multi-Centre, Extension Trial, Evaluating the Long-Term Progression-Free Survival of XXXXX or XXXXX Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy
 124. A Prospective, Multi-Center Prostate Cancer Individual Signature Evaluation (PRECISE) Trial in Patients Undergoing Scheduled Prostate Biopsy
 125. A Randomized, Double-Blind, Phase II, Efficacy and Safety Study of XXXXX (XXXXX) vs XXXXX in Castrate Men with Metastatic Prostate Cancer

126. Efficacy and Safety of a New XXXXX XXXXX 22.5mg Depot Formulation in the Treatment of Prostate Cancer
127. A Randomized, Open-Label, Phase 2 Trial Examining the Sequencing of XXXXX and Androgen Deprivation Therapy in Men with Non-Metastatic Prostate Cancer and a Rising Serum Prostate Specific Antigen After Primary Therapy
128. Phase II, Open Label, Dose Finding Study of the Effect of XXXXX on Total and Free Testosterone Levels in Men with Prostate Cancer Compared to a Luteinizing Hormone Releasing Hormone Agonist
129. Open label study of the effect of XXXXX on serum PSA and free testosterone levels in men with castration resistant prostate cancer and maintained on androgen deprivation therapy
130. Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of XXXXX for the Treatment of BPH: Two Doses 1-7 Years Apart
131. An International, Multi-Center, Open Label, Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of XXXXX versus XXXXX Depot (XXXXX) in Men with Prostate Cancer
132. A Randomized Phase 3 Study Comparing Standard First-Line XXXXX/XXXXX to XXXXX/XXXXX in Combination with XXXXX (XXXXX) in Men with Metastatic Castrate Resistant Prostate Cancer
133. The Caris Biorepository Research Protocol
134. Efficacy and Safety of a New XXXXX XXXXX 22.5mg Depot Formulation in the Treatment of Prostate Cancer
135. ERGa/PSA High Volume Urine Sample Collection
136. RGa/PSA in Urine – mRNA Stability Study Protocol
137. Development Clinical Sample Collection Protocol
138. Open-Label, Multi-Centre, Parallel Group Dose-Escalation Trial Assessing the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Intramuscular Injections of XXXXX Administered in 1-Month Dosing Regimens in Patients with Prostate Cancer
139. A Randomized, Double-Blind, Placebo-Controlled Evaluation of XXXXX for On-Demand Treatment of Men with Erectile Dysfunction
140. A Multicenter Phase 2, Randomized, Double-Blind, Efficacy and Safety Study of XXXXX vs XXXXX in Men with Prostate Cancer who have Failed Androgen Deprivation Therapy
141. A Randomized, Double-Blind, Parallel, Placebo-Controlled, Phase 4, Multi-Center Study to Assess Efficacy and Safety of XXXXX (XXXXX) to Improve Urinary Continence of Subjects After Robotic Assisted Radical Prostatectomy
142. A Phase IIa Randomized, Placebo-Controlled Trial of Single High Dose XXXXX and Daily XXXXX (XXXXX) Versus Placebo In Men with Early Stage Prostate Cancer Undergoing Prostatectomy

143. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Clinical Trial of the Effect of XXXXX (XXXXX) on Spermatogenesis in Healthy Adult Males and Adult Males with Mild Erectile Dysfunction